BNET Industries

Urologix Inc.

(ULGX) is in the Health Care Industry

Market Cap:$14.1M
Last Fiscal Year Sales:$14.9M
  • Public
  • US
Dow Jones Description

Urologix develops, manufactures, and markets non-surgical, catheter-based therapies that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a disease that affects more than 23 million men worldwide. We market our control units under the Targis ® and CoolWave ® names and our procedure kits under the CTC, Targis, Prostaprobe and the recently approved CTC Advance names. All systems utilize the Companys Cooled ThermoTherapy technology, a targeted microwave energy combined with a unique cooling mechanism that protects healthy tissue and enhances patient comfort while providing safe, effective, lasting relief from the symptoms of BPH. Cooled ThermoTherapy can be performed without general anesthesia or intravenous sedation and can be performed in a physicians office or an outpatient clinic. We believe that Cooled ThermoTherapy provides an efficacious, safe and cost-effective solution for BPH with results clinically superior to medication and without the complications and side effects inherent in surgical procedures. We believe that third-party reimbursement is essential to the continued adoption of Cooled ThermoTherapy, and that clinical efficacy, overall cost-effectiveness and physician advocacy will be keys to maintaining such reimbursement. We estimate that 60% to 80% of patients who receive Cooled ThermoTherapy treatment in the United States will be eligible for Medicare coverage. ...

Number of Employees 86
Contact Information

14405 21st Ave N

Minneapolis, Minnesota 55447-4685

urologix.com

(763) 475-1400

NAICS Code Electromedical and Electrotherapeutic Apparatus Manufacturing: 334510

Recent Events

  • Urologix Releases Results for 1Q Fiscal Year 2010

    10/30/09 - Financial Announcement - View Story

News & Analysis

urologix inc. - All News and Analysis

  • Urologix Inc. F4Q08 (Qtr End 06/30/08) Earnings Call Transcript

    Seeking Alpha - 2008-09-23

    Question-and-Answer Session Operator Operator Instructions Your first question comes from [Ernie Enbird – Felt and Company]. Ernie Enbird – Felt and Company You talk about a focus on driving sales. Does that mean that the operating expense lines are sort of where you expect them...

    Tags: Urologix Inc.

advertisement
     ULGX $0.98 +0.04 (4.26% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 16,734
Shares Outstanding 14.49M
Market Cap 14.2M
Year High 1.31
Year Low 0.21
Earnings Per Share -0.26
P/E Ratio -3.77
Dividend N/A
Yield N/A
IndustryTop Rated
advertisement